In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare ...

CSPC Pharmaceutical Group Ltd. announced June 13 that it struck a potential $5.33 billion deal with Astrazeneca plc to ...

A new AI-driven framework, MapDiff, enhances inverse protein folding accuracy, accelerating the design of proteins for ...

CSPC Pharmaceutical Group Ltd. has entered into a strategic research collaboration agreement with Astrazeneca plc for the discovery and development of novel oral small-molecule candidates utilizing ...

AstraZeneca and CSPC Pharmaceutical have signed a research deal worth up to USD 5.3 billion to co-develop oral therapies for chronic and immunological diseases. CSPC will lead discovery in China using ...

Two key protein structures in the body are being visualized for the first time, thanks in part to the latest technology in ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value ...

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has ...

The global cutaneous lupus erythematosus market is experiencing significant growth, driven by novel biologic therapies and personalized medicine. With rising autoimmune disease incidence, enhanced ...